不同剂量新活素在急诊PCI治疗急性心肌梗死中的效果与安全性  

Effects and Safety of Different Doses of rhBNP in Emergency PCI for the Treatment of Acute Myocardial Infarction

在线阅读下载全文

作  者:刘钰 卢士建 王琛 LIU Yu;LU Shijian;WANG Chen(Department of Emergency Internal Medicine,Xinyang Central Hospital,Xinyang 464000,China;Department of Cardiology,Xinyang Central Hospital,Xinyang 464000,China)

机构地区:[1]信阳市中心医院急诊内科,河南信阳464000 [2]信阳市中心医院心内科,河南信阳464000

出  处:《临床医学工程》2024年第10期1245-1246,共2页Clinical Medicine & Engineering

摘  要:目的分析不同剂量新活素在急诊经皮冠状动脉介入(PCI)治疗急性心肌梗死中的效果与安全性。方法64例急性心肌梗死患者随机分为两组。在急诊PCI治疗期间,A组给予0.01μg·kg^(-1)·min^(-1)新活素,B组给予0.015μg·kg^(-1)·min^(-1)新活素,持续给药24 h。比较两组的治疗效果、血管内皮功能以及不良反应。结果两组的治疗总有效率、不良反应发生率比较,差异无统计学意义(P>0.05)。治疗后,B组的ET-1明显低于A组,NO明显高于A组(P<0.05)。结论大剂量新活素可明显改善急诊PCI治疗的急性心肌梗死患者的临床症状,提升其血管内皮功能,且不会增加用药风险。Objective To analyze the effects and safety of different doses of rhBNP in emergency percutaneous coronary intervention(PCI)for the treatment of acute myocardial infarction.Methods 64 patients with acute myocardial infarction were randomly divided into two groups.During emergency PCI treatment,group A was given 0.01μg·kg^(-1)·min^(-1) rhBNP,and group B was given 0.015μg·kg^(-1)·min^(-1) rhBNP for 24 h continuously.The therapeutic effect,vascular endothelial function and adverse reactions were compared between the two groups.Results No significant difference was found in the total effective rate and incidence of adverse reactions between the two groups(P>0.05).After treatment,ET-1 in group B was significantly lower than that in group A,and NO was significantly higher than that in group A(P<0.05).Conclusions High-dose rhBNP can obviously improve the clinical symptoms of patients with acute myocardial infarction treated by emergency PCI,and improve their vascular endothelial function,without increase of medication risk.

关 键 词:新活素 急诊PCI 急性心肌梗死 血管内皮功能 疗效 安全性 

分 类 号:R542.22[医药卫生—心血管疾病]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象